Asier Antoñana Vildósola (@antonanaasier) 's Twitter Profile
Asier Antoñana Vildósola

@antonanaasier

PhD in Cancer Immunology @CICbioGUNE | Fellow @FundlaCaixa | Interested in tumor immunology, synthetic biology & glycobiology

ID: 1434534044721688576

linkhttp://linkedin.com/in/asierantonana calendar_today05-09-2021 15:09:14

7 Tweet

83 Followers

308 Following

CIC bioGUNE (@cicbiogune) 's Twitter Profile Photo

#bioGUNE_Thesis | Researcher Asier Antoñana Vildósola will defend his #PhD thesis: 📖 “Study of the Siglec-15–CD11b axis in T cell function: Mechanism of action and therapeutic opportunities” 👤 Asis Palazon 🔗 ow.ly/2T1F50Srz4x 🕜 Thursday, July 11th, 11:30H

#bioGUNE_Thesis | Researcher <a href="/AntonanaAsier/">Asier Antoñana Vildósola</a> will defend his #PhD thesis:

📖 “Study of the Siglec-15–CD11b axis in T cell function: Mechanism of action and therapeutic opportunities”
👤 <a href="/asispalazon/">Asis Palazon</a>
🔗 ow.ly/2T1F50Srz4x
🕜 Thursday, July 11th, 11:30H
Asier Antoñana Vildósola (@antonanaasier) 's Twitter Profile Photo

PhD-efeated! 🎉 Happy to announce I defended my thesis on July 11th. Heartfelt thanks to the AP lab, and the committee David Sancho, ArkaitzCarracedoLAB, and Casanova Acebes Lab for your invaluable insights. Honored to discuss my work with experts I look up to. 🔬 👤Asis Palazon 🏛️@CICBIOGUNE

PhD-efeated! 🎉 Happy to announce I defended my thesis on July 11th. Heartfelt thanks to the AP lab, and the committee <a href="/SanchoLab/">David Sancho</a>, <a href="/ArkaitzLab/">ArkaitzCarracedoLAB</a>, and <a href="/Casanova_Acebes/">Casanova Acebes Lab</a> for your invaluable insights. Honored to discuss my work with experts I look up to. 🔬
👤<a href="/asispalazon/">Asis Palazon</a>
🏛️@CICBIOGUNE
SoniaGuedan (@guedans) 's Twitter Profile Photo

Our latest work is out in Molecular Therapy! We present ARI0003, dual-targeting CD19/BCMA CAR-T cells for lymphoma. We performed an exhaustive characterization of strategies to generate dual CAR-T cells. This CAR-T therapy is now under clinical investigation. ➡️ cell.com/molecular-ther…

Our latest work is out in <a href="/MolTherapy/">Molecular Therapy</a>! We present ARI0003, dual-targeting CD19/BCMA CAR-T cells for lymphoma. We performed an exhaustive characterization of strategies to generate dual CAR-T cells. This CAR-T therapy is now under clinical investigation.
➡️ cell.com/molecular-ther…